Dublin, April 24, 2026 (GLOBE NEWSWIRE) — The “Infectious Disease Clinical Trials Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The infectious disease clinical trials market has been experiencing strong growth, with projections indicating expansion from $15.1 billion in 2025 to $16.13 billion in 2026 at a CAGR of 6.8%. The surge during this period can be attributed to a heightened global burden of infectious diseases, increased funding for vaccine development, and the widespread adoption of digital trial management systems. The integration of AI-assisted patient recruitment and global trial decentralization are driving further growth, with market size expected to reach $21.25 billion by 2030 at a CAGR of 7.1%.
Key trends shaping the market include data-driven trial designs, decentralized trial models, and the integration of real-world evidence. Enhanced healthcare infrastructure, defined by advanced medical services and technology, is pivotal to this growth, facilitating the handle of emerging diseases, improving diagnostic and treatment facilities, and ultimately expanding trial capabilities. A notable development is the projected growth in U.S. hospitals to 6,093 by 2025, supporting robust infrastructure expansion.
Market players like Roche and Flourish Research LLC are actively advancing in this sector. Roche initiated a Phase 3 clinical trial in May 2025 for zosurabalpin, a promising antibiotic targeting CRAB, showcasing a unique mechanism without reported resistance. Flourish Research LLC’s acquisition of Diablo Clinical Research LLC further underscores efforts to broaden trial capabilities and geographic reach.
The market features prominent players including GlaxoSmithKline, Pfizer, Moderna, and others, with North America leading the region by 2025. Meanwhile, Asia-Pacific is anticipated to be the fastest-growing region moving forward. However, tariffs are impacting the market by raising costs for essential trial materials, prompting a shift toward regional infrastructure development and digital trial adoption.
Overall, the infectious disease clinical trials market comprises revenues from services such as patient recruitment, data management, laboratory testing, and regulatory compliance, among others. These services are critical for advancing trial objectives and gaining insights necessary for combating infectious diseases effectively.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026 – 2030 |
| Estimated Market Value (USD) in 2026 | $16.13 Billion |
| Forecasted Market Value (USD) by 2030 | $21.25 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
Global Infectious Disease Clinical Trials Market Trends and Strategies
- Increasing Adoption of Data-Driven Trial Design
- Rising Use of Decentralized Clinical Trial Models
- Growing Integration of Real-World Evidence
- Expansion of Adaptive Trial Methodologies
- Enhanced Focus on Rapid Pathogen Response
- Artificial Intelligence & Autonomous Intelligence
- Biotechnology, Genomics & Precision Medicine
- Digitalization, Cloud, Big Data & Cybersecurity
- Industry 4.0 & Intelligent Manufacturing
- Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
Companies Featured
- GlaxoSmithKline plc (GSK)
- Pfizer Inc
- Moderna Inc
- Novartis AG
- Sanofi S.A.
- AstraZeneca plc
- Merck & Co Inc
- Gilead Sciences Inc
- AbbVie Inc
- Eli Lilly and Company
- Bristol Myers Squibb Company
- Roche Holding AG
- Bayer AG
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Regeneron Pharmaceuticals Inc
- Biogen Inc
- Amgen Inc
- Inovio Pharmaceuticals Inc
- Dynavax Technologies Corporation
- Valneva SE
- Emergent BioSolutions Inc
- Vir Biotechnology Inc
- International AIDS Vaccine Initiative
- VBI Vaccines Inc
- Otsuka Pharmaceutical Co Ltd
- Daiichi Sankyo Company Limited
- Shionogi & Co Ltd
- Astellas Pharma Inc
- Eisai Co Ltd
- Sun Pharmaceutical Industries Ltd
- Glenmark Pharmaceuticals Ltd
- Bharat Biotech International Limited
- Laurus Labs Limited
- Sarepta Therapeutics Inc
- Alnylam Pharmaceuticals Inc
- Intellia Therapeutics Inc
- Sangamo Therapeutics Inc
- Excision BioTherapeutics Inc
- Atara Biotherapeutics Inc
- Adaptive Biotechnologies Corporation
- ImmunityBio Inc
- Enanta Pharmaceuticals Inc
- Iterum Therapeutics plc
- Spero Therapeutics Inc
- Venatorx Pharmaceuticals Inc
- Vaxart Inc
- Immunovant Inc
- Tonix Pharmaceuticals Holding Corp
- Genentech Infectious Diseases Unit
For more information about this report visit https://www.researchandmarkets.com/r/7wev2z
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Infectious Disease Clinical Trials Market
